Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Zoom Video Communications, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Zoom Video Communications, Inc. trades at $90.12 (market cap $26.32B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Zoom Video Communications, Inc. is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ZM | |
|---|---|---|
Market Cap | $39.89B | $26.32B |
Sector | Health | Technology |
52-Week High | $491.22 | $111.88 |
52-Week Low | $278.09 | $69.77 |
Enterprise Value | $38.15B | $18.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Zoom Communications (ZM) trades at $89.76, showing modest daily movement with a slight 0.13% decline. The stock maintains bullish technical signals with strong moving average support and trades near pivot point resistance at $91. Fundamentally, Zoom demonstrates robust profitability with 77.4% gross margins and 42% net income margins, while recent Q1 2026 earnings beat expectations. The company continues expanding AI capabilities through acquisitions like Common Room and new Virtual Agent offerings.
Zoom presents a compelling value opportunity trading below analyst consensus targets with 32% upside potential. Strong cash generation, AI integration progress, and strategic Anthropic investment provide catalysts, though competitive pressures from Microsoft and Google remain key risks. Wall Street maintains cautious optimism with mixed analyst ratings reflecting growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
